Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The role of race in heart failure therapy.

Literature DB >> 11960591

The role of race in heart failure therapy.

Abstract

Heart failure in blacks is a unique malady characterized by a different natural history, more worrisome prognosis, and potential variances in the response to current medical therapy for heart failure. The overwhelming burden of hypertension as a putative cause of left ventricular dysfunction identifies this illness. Although differences in the response to medical therapy have been described, angiotensin-converting enzyme inhibitors and beta-blockers remain the most appropriate therapy. Certain genetic polymorphisms may exist that explain the observed differences.

Entities: Disease

Mesh：

Substances：

Year: 2002 PMID： 11960591 DOI： 10.1007/s11886-002-0054-0

Source DB: PubMed Journal: Curr Cardiol Rep ISSN： 1523-3782 Impact factor: 2.931

25 in total

Review 1. Molecular basis of ethnic differences in drug disposition and response.

Authors: H G Xie; R B Kim; A J Wood; C M Stein
Journal: Annu Rev Pharmacol Toxicol Date: 2001 Impact factor: 13.820

2. Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C.

Authors: J D Moore; D A Mason; S A Green; J Hsu; S B Liggett
Journal: Hum Mutat Date: 1999-09-19 Impact factor: 4.878

3. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors: Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal: N Engl J Med Date: 2001-05-31 Impact factor: 91.245

4. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor.

Authors: D A Mason; J D Moore; S A Green; S B Liggett
Journal: J Biol Chem Date: 1999-04-30 Impact factor: 5.157

5. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.

Authors: M Packer; G V Antonopoulos; J A Berlin; J Chittams; M A Konstam; J E Udelson
Journal: Am Heart J Date: 2001-06 Impact factor: 4.749

6. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

Authors: C W Yancy; M B Fowler; W S Colucci; E M Gilbert; M R Bristow; J N Cohn; M A Lukas; S T Young; M Packer
Journal: N Engl J Med Date: 2001-05-03 Impact factor: 91.245

Review 7. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors: J N Cohn; R Ferrari; N Sharpe
Journal: J Am Coll Cardiol Date: 2000-03-01 Impact factor: 24.094

8. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators.

Authors: M G Bourassa; O Gurné; S I Bangdiwala; J K Ghali; J B Young; M Rousseau; D E Johnstone; S Yusuf
Journal: J Am Coll Cardiol Date: 1993-10 Impact factor: 24.094

Review 9. The pharmacology of carvedilol.

Authors: R R Ruffolo; M Gellai; J P Hieble; R N Willette; A J Nichols
Journal: Eur J Clin Pharmacol Date: 1990 Impact factor: 2.953

10. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage.

Authors: M Suthanthiran; B Li; J O Song; R Ding; V K Sharma; J E Schwartz; P August
Journal: Proc Natl Acad Sci U S A Date: 2000-03-28 Impact factor: 11.205

3 in total